Method of treating the syndrome of coronary heart disease risk factors in humans

a risk factor and human syndrome technology, applied in the field of human syndrome of coronary heart disease risk factors, can solve the problems of inability to correct the entire hyperlipidemic complex with a single therapeutic agent, the exact interrelationship between the disease states that make up these syndromes is not fully understood, and the lipid fraction of dyslipidemia may be predominan

a risk factor and human syndrome technology, applied in the field of human syndrome of coronary heart disease risk factors, can solve the problems of inability to correct the entire hyperlipidemic complex with a single therapeutic agent, the exact interrelationship between the disease states that make up these syndromes is not fully understood, and the lipid fraction of dyslipidemia may be predominan

US20050250701A1Inactive Publication Date: 2005-11-10CPD LLC
31 Cites 8 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating the syndrome of coronary heart disease risk factors in humans

Examples

Experimental program
Comparison scheme
Effect test

example

[0059] The example is being described for purely illustrative purposes, and is in no way meant to limit the scope of the invention.

[0060] The daily blood glucose profile of a 72 year old subject with Type 2 Diabetes and dyslipidemia was monitored following the early morning oral administration of 0.15 mg Hydrocodone, a centrally acting i-agonist in combination with sulfonylurea type insulin secretagogue. The glucose profile of the subject was monitored on the second day after the treatment had been initiated. Sufficient time was allowed after the earlier treatment to eliminate any carry-over effect.

Treatment 1(-◯-) no drug treatment.Breakfast: 08:40-09:00; lunch: 12:25-12:50; dinner: 18:40-19:00time [h]08:1010:0012:2014:0018:3020:00BG [mg / dL]13215610415098117Treatment 2(-□-) 0.15 Hydrocodone, a centrally acting μ-agonist in combination with 1.0 mgGlipizide, administered 2 hours before breakfastBreakfast: 09:00-0915; lunch: 12:10-12:30; dinner: 19:20-19:50Time08:4509:0009:1509:501...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationsaaaaaaaaaa
biologic half lifeaaaaaaaaaa
Insulin Resistanceaaaaaaaaaa
Login to View More

Abstract

The invention provides an improved method of treating a human suffering from one or more conditions included within the Coronary Heart Disease Risk Factor (CHDRF) syndrome. The method includes administering, by a pharmaceutically effective mode, a drug composition having an opioidergic agent including an opiate antagonist, opiate having μ-agonist activity or combination thereof, and an insulin secretagogue.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application is a continuation-in-part of and claims priority to U.S. Application No. 09 / 639,061 filed on Aug. 15, 2000.BACKGROUND OF THE INVENTION [0002] Coronary Heart Disease Risk Factors (CHDRFs) are major causes of death in the industrialized world. CHD risk factors include Type 2 Diabetes (and its precursor, Impaired Glucose Tolerance (IGT)), hyperlipidemia or dyslipidemia, overweight, obesity and essential hypertension, i.e., a form of hypertension that occurs without a discoverable organic cause. The CHDRF syndrome may, therefore, be defined as a group of interrelated disorders: Type 2 Diabetes, IGT, Dyslipidemia, Overweight, Obesity and essential hypertension. It has also become apparent that Type 2 Diabetes, by itself, represents a syndrome of various, in part sequential, disease states which interact with other components of the CHDRF syndrome. However, the exact interrelationships between the disease states that make up t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
10 Nov 2005
Publication
US20050250701A1
IPC
A61K31/00; A61K31/135; A61K31/4184; A61K31/44; A61K31/445; A61K31/4468; A61K31/451; A61K31/485; A61K38/22; A61K38/26; A61K38/33; A61K45/06; A61P9/00
CPC
A61K31/00; A61K38/2278; A61K31/137; A61K31/4184; A61K31/44; A61K31/445; A61K31/4468; A61K31/451
Inventors
CLEMENS, ANTON H.